[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-fibrillation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,45,59,81,115,144,162,187,220,248,278,310,342,370,395,422,451,480,535,559],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054135","parasternal-extravascular-icd-system-pivotal-clinical-investigation-alarion-ev-study-100054135",false,"NCT07324031","Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study","ALARION EV","Inclusion Criteria:\n\n1. At least 18 years old\n2. Class I or IIa indication for implantation of an ICD according to the ACC\u002FAHA\u002FHRS Guidelines or ESC guidelines\n\nExclusion Criteria:\n\n1. Patients who cannot read or write\n2. Expected survival \\\u003C 1 year\n3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period\n4. Participation in any concurrent clinical study without prior approval from the Sponsor\n5. Inability or unwillingness to provide informed consent to participate in the study\n6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit\n7. Circumstances that may prevent data collection or completion of specified follow-up visits\n8. Allergies to any device materials listed in the Instructions for Use (IFU)\n9. Contraindication for temporary suspension of oral\u002Fsystemic anticoagulation\n10. Known history of lung disease with FEV1 \\\u003C 1.0 Liter\n\n    Device Related:\n11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator\n12. Implanted with a subcutaneous ICD lead, subcutaneous coils\u002Farrays, epicardial patches or epicardial pace\u002Fsense leads\n13. Any known need for MRI prior to approval of MRI conditional labeling\n\n    Anatomy Related:\n14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure\n15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead\n16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type\n17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)\n18. History of thoracic radiation therapy or other medical treatments\u002Fconditions which may complicate the Parasternal EV-ICD System implant procedure\n19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax\n20. Surgically corrected congenital heart disease (not including catheter-based procedures)\n\n    Cardiac Related:\n21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy\n22. Decompensated heart failure\n23. Currently on inotropic therapy\n24. Known history of pericardial disease, pericarditis or mediastinitis\n25. Risk factors associated with defibrillation testing:\n\n    * Severe aortic stenosis\n    * Current Intracardiac LA or LV thrombus\n    * Severe proximal three-vessel or left main coronary artery disease without revascularization\n    * Hemodynamic instability\n    * Unstable angina\n    * Recent stroke or transient ischemic attack (within the last 3 months)\n    * Known inadequate external defibrillation\n    * LVEF \\\u003C 20% (most recent assessment; must be within 180 days of consent)\n    * LVEDD \\>70 mm (most recent assessment; must be within 180 days of consent)","ALL","18 Years",{"count":19,"type":20},280,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.\n\nThe objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.",[26,27,28],"Ventricular Arrythmia","Ventricular Fibrillation","Ventricular Tachycardia",[30,31],"Ventricular Defibrillation","Extravascular","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-07-02",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"AtaCor Medical, Inc.","INDUSTRY",35,{"id":46,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":24,"conditions":49,"keywords":50,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":4},"100617854",{"count":19,"type":20},[23],[26,27,28],[30,31],"NOT_YET_RECRUITING","2026-06-26",{"date":54,"type":36},"2026-06-30",{"date":56,"type":20},"2026-07-01",{"date":40,"type":20},{"name":42,"class":43},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100573399","evolution-of-intracardiac-electrograms-recorded-by-left-bundle-branch-pacing-lead-in-patients-with-icd-or-crt-d-100573399","NCT06745778","Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D","Inclusion Criteria:\n\n* Patients aged \\>=18 yrs.\n* Patients indicated for ICD or CRT-D (primary or secondary prevention)\n* Patients who recently (\\\u003C=30 days) received ICD\u002FCRT-D implantation with LBBP\n* Patients' EGM can be digitally recorded\n* Patients are willing to participate in the study and provide signed informed consent\n\nExclusion Criteria:\n\n* Patients received CIED upgrade or replacement with old pacing leads\n* Patients are pregnant\n* Patients participate in another study that will confound this study",{"count":66,"type":20},50,"OBSERVATIONAL","The goal of this observational study is to investigate the changes of LBB EGM during daily activities and overdrive pacing at the time of peri-implantation and up to 6-month follow-ups of ICD\u002FCRT-D patients. The main question it aims to answer is:\n\n• Does the LBBP lead can provide accurate, stable, and valid EGM for ICD\u002FCRT-D sensing and detection of ventricular tachyarrhythmia events? In each patient intracardiac EGMs of LBBP lead will be collected by ambulatory Holter monitor at the time of peri-implantation and up to 6-month follow-up. EGM collection will be collected at resting and walking conditions and overdrive pacing.",[70,27],"Ventricular Tachycardia (VT)","2026-05-06",{"date":73,"type":36},"2026-05-08",{"date":75,"type":36},"2025-02-26",{"date":77,"type":20},"2026-07-31",{"name":79,"class":43},"Medtronic Cardiac Rhythm and Heart Failure",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":67,"phases":4,"briefSummary":93,"conditions":94,"keywords":104,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100489526","development-of-circ-technologies-100489526","NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",true,{"count":91,"type":20},1000,"20 Years","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[95,96,97,98,99,100,101,102,103,27],"Cardiovascular Diseases","Heart Failure","Ischemic Heart Disease","Non-ischemic Cardiomyopathy","Valvular Heart Disease","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation",[105],"MRI",{"date":73,"type":36},{"date":108,"type":36},"2022-09-09",{"date":110,"type":20},"2042-09-09",{"name":112,"class":113},"The Cleveland Clinic","OTHER",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":131,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":114},"100637044","abdominal-aortic-tourniquet-application-for-non-traumatic-out-of-hospital-cardiac-arrest-100637044","NCT07573566","Abdominal Aortic Tourniquet Application for Non-Traumatic Out-of-Hospital Cardiac Arrest","ATTICA","Inclusion Criteria:\n\n* Cardiac arrest with indication for initiation of resuscitation\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Pregnancy (suspected or confirmed)\n* Age \\\u003C 18 years\n* Abdominal circumference does not allow application of the AAJT\n* Traumatic etiology\n* Planned eCPR or other intervention in which study inclusion would delay the standard of care\n* Known abdominal aortic aneurysm",{"count":123,"type":20},5,[23],"The aim of the study is to investigate whether occluding the abdominal aorta with an external device could be a potential therapeutic option in cases of non-traumatic cardiac arrest occurring outside of a hospital.\n\nIn cardiac arrest, the heart suddenly stops beating, causing the circulation of blood to collapse. In this situation, vital organs-especially the brain and the heart itself-are no longer adequately supplied with oxygen. Without immediate treatment, severe damage or death occurs within minutes.\n\nThe study therefore examines a specific intervention: the temporary occlusion of the abdominal aorta, which carries blood to the lower regions of the body. If this artery is blocked for a short period, the available blood can be redirected more effectively to the upper parts of the body. In theory, this could improve the oxygen supply to these organs and increase the likelihood that the heart will resume beating or that neurological damage can be reduced.",[127,128,129,130,27],"Cardiac Arrest (CA)","Out-of-hospital Cardiac Arrest (OHCA)","Asystole","Pulseless Electrical Activity",[132,133,134],"AAJT","OHCA","Aortic occlusion","2026-04-30",{"date":137,"type":36},"2026-05-07",{"date":139,"type":20},"2026-08",{"date":141,"type":20},"2027-09",{"name":143,"class":113},"Klinikum Klagenfurt am Wörthersee",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100599224","longitudinal-validation-of-circ-technologies-100599224","NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":91,"type":20},"Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[95,96,97,98,99,100,101,102,103,27],[105],"2026-03-19",{"date":156,"type":36},"2026-03-23",{"date":158,"type":20},"2026-04",{"date":160,"type":20},"2037-08",{"name":112,"class":113},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":114},"100521616","emergency-resuscitative-endovascular-balloon-occlusion-of-the-aorta-in-out-of-hospital-cardiac-arrest-100521616","NCT06071910","Emergency Resuscitative Endovascular Balloon Occlusion of the Aorta in Out of Hospital Cardiac Arrest","ERICA-ARREST","Inclusion criteria\n\n* Non-Traumatic OHCA in patients within the East of England area AND with a East Anglian Air Ambulance (EAAA) REBOA team in attendance\n* Patients below or equal to 80yrs of age and above or equal to 18yrs of age, according to available information\u002Festimate at scene\n* No flow \\\u003C10 mins from data available (i.e. total period in OHCA with no CPR)\n* In cardiac arrest (with no sustained ROSC) on arrival of the EAAA REBOA team\n\nExclusion criteria\n\n* Patients aged less than 18 or above 80 years\n* Known terminal illness\n* Multiple severe co-morbidities\n* Traumatic Cardiac Arrest (TCA)\n* Inability to deploy mechanical CPR (e.g. LUCAS Device)\n* Pregnancy, obvious or suspected","80 Years",{"count":171,"type":20},40,[23],"This study will assess the feasibility of performing pre-hospital resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct to conventional Advanced Life Support (ALS) in patients suffering from non-traumatic out of hospital cardiac arrest (OHCA). As well as providing valuable insights into the technical feasibility of performing this procedure as part of a resuscitation attempt, the study will also document the beneficial physiological effects of REBOA in this group of patients.",[175,176,177,27,26,130],"Out-Of-Hospital Cardiac Arrest","Cardiac Arrest","Cardiac Arrhythmia","2026-02-26",{"date":180,"type":36},"2026-03-02",{"date":182,"type":36},"2024-06-04",{"date":184,"type":20},"2026-12-31",{"name":186,"class":113},"Queen Mary University of London",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":200,"conditions":201,"keywords":207,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100606394","phase-2-early-double-sequential-defibrillation-in-out-of-hospital-cardiac-arrest-100606394","NCT07174986","Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest","\"A Randomized Trial Assessing the Effect of Early Double Sequential Defibrillation With Anterior-posterior and Anterior Lateral Pad Placement and Sequential Defibrillation Compared to Standard Pad Placement and Single Defibrillation in Patients With Out of Hospital Cardiac Arrest With Initial Shockable Rhythm and at Least One Failed Standard Defibrillation\"","DOUBLE D","Inclusion Criteria:\n\n* OHCA patients with VT\u002FVF at first rhythm analysis and at least one defibrillation performed in standard (A-L) position\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Obvious pregnancy\n* Known preexisting Do Not Attempt Resuscitation order",{"count":196,"type":20},916,[198,199],"PHASE2","PHASE3","Some of the patients affected by Out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation (VF)\u002Fventricular tachycardia (VT) do not respond to initial defibrillation. The survival decreases with number of defibrillations required to terminate VF\u002FVT. In 2022, one prospective cluster randomized trial showed increased survival among (OHCA) patients in refractory VF using Double Sequential Defibrillation (DSD). If DSD can increase survival among all patients in VF that dont respond to one defibrillation, i.e. before it has become refractory is not known.\n\nThe aim of this trial is to assess survival with a double defibrillation strategy initiated as soon as possible among patients with Out of Hospital Cardiac Arrest with initial shockable rhythm and at least one failed standard defibrillation, compared with continued resuscitation using standard defibrillation.",[202,27,203,204,205,206],"Out of Hospital Cardiac Arrest","Defibrillation","CPR","ACLS","Sudden Death",[208,209,205],"Double sequential defibrillation","Double sequential external defibrillation","2026-02-12",{"date":212,"type":36},"2026-02-17",{"date":214,"type":36},"2025-09-08",{"date":216,"type":20},"2029-12",{"name":218,"class":113},"Gabriel Riva",14,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100619774","predicting-severe-cardiac-arrhythmias-in-the-perioperative-period-using-ai-ecg-100619774","NCT07348991","Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG","Predicting Atrial Fibrillation and Life-threatening Cardiac Arrhythmias and Conduction Disorders in the Perioperative Period in High Cardiac Risk Surgery Using Artificial Intelligence Elements","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Scheduled surgery with high cardiac risk\n* Informed consent was given to participate in the study\n\nExclusion Criteria:\n\n* Cancellation of the surgery for any reason;\n* The patient's unwillingness to continue participating in the study;\n* Poor quality of the ECG recording on a single-channel ECG monitor.",{"count":228,"type":20},300,"During the preoperative examination, in addition to the standard examination recommended before high-risk cardiac surgeries, a digital single-lead ECG is recorded using portable CardioQUARK devices. This ECG is analyzed for time, amplitude, and frequency parameters-more than 200 parameters per cardiac cycle. Additionally, the available parameters of a standard 12-lead ECG recording are determined. All parameters of both single-lead and 12-lead ECGs will be included in a multivariate regression analysis to determine the optimal method for predicting atrial fibrillation, life-threatening cardiac arrhythmias, and conduction abnormalities in the perioperative period after high-risk cardiac procedures.\n\nThe study will include patients undergoing high-risk cardiac surgeries, such as those on the heart, aorta, esophagus, pancreas, liver, and lungs, as well as high-risk oncological surgeries. A partial analysis will also be performed depending on the type of intervention. Rhythm and conduction disturbances will be recorded during surgery, as well as in the postoperative period, using ECG monitors, 24-hour ECG monitoring, and repeated recordings of a standard ECG when complaints or signs of unstable hemodynamics arise",[103,231,232,70,27],"Atrioventricular Block, Second and Third Degree","Sinus Node Dysfunction",[234,235,236,237,238,239],"Electrocardiogram","Artificial intelligence","Cardiac arrhythmias","Atrioventricular block","Perioperative","Atrial fibrillation","2026-02-09",{"date":242,"type":36},"2026-02-10",{"date":184,"type":20},{"date":245,"type":20},"2028-05-30",{"name":247,"class":113},"I.M. Sechenov First Moscow State Medical University",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":114},"100537757","phase-3-study-evaluating-dexmedetomidine-in-the-acute-treatment-of-electrical-storm-100537757","NCT06281977","Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm","SEDATE","Inclusion Criteria:\n\n\\- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.\n\nExclusion Criteria:\n\n* Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors\n* SCAI class D or E cardiogenic shock\n* Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.\n* ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.\n* Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.\n* Pregnancy\n* Known dexmedetomidine allergy or intolerance\n* Inability to obtain consent from patient or substitute decision maker.\n* Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization",{"count":256,"type":20},192,[199],"The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.",[28,260,27,261],"Ventricular Arrhythmias","Recurrent Ventricular Tachycardia",[263,264,265,266,267,261,268],"Electrical Storm","Dexmedetomidine","Ventricular Electrical Storm","Precedex","Recurrent Ventricular Arrhythmias","Sedation","2025-12-16",{"date":271,"type":36},"2025-12-17",{"date":273,"type":36},"2024-05-08",{"date":275,"type":20},"2027-08-01",{"name":277,"class":113},"Ottawa Heart Institute Research Corporation",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":21,"phases":288,"briefSummary":290,"conditions":291,"keywords":295,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100349185","phase-4-epinephrine-dose-optimal-versus-standard-evaluation-trial-100349185","NCT03826524","Epinephrine Dose: Optimal Versus Standard Evaluation Trial","CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)","EpiDOSE","Inclusion Criteria:\n\n* Out-of-hospital cardiac arrest treated by paramedics\n* Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessed by EMS (paramedic or fire)\n* Established intravenous vascular access\n\nExclusion Criteria:\n\n* Known or apparent age \\\u003C18 years\n* Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics\n* Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)\n* Administration of intramuscular, endotracheal tube, or intraosseous epinephrine\n* Prisoners or persons in police custody\n* Known allergy or sensitivity to epinephrine",{"count":287,"type":20},3790,[289],"PHASE4","The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients.",[292,293,27,294],"Cardiac Arrest, Out-Of-Hospital","Sudden Cardiac Arrest","Ventricular Tachycardia-Pulseless",[296,297,298,299],"out-of-hospital cardiac arrest","sudden cardiac arrest","epinephrine","randomized controlled trial","2025-12-09",{"date":302,"type":36},"2025-12-11",{"date":304,"type":36},"2023-05-24",{"date":306,"type":20},"2028-12",{"name":308,"class":113},"Unity Health Toronto",8,{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":21,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":341},"100518021","prehospital-resuscitation-intranasal-cooling-effectiveness-survival-study-2-100518021","NCT06025123","Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2","Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2 (PRINCESS2)","PRINCESS2","INCLUSION CRITERIA:\n\nPatients ≥18 years that meet all of the following inclusion criteria:\n\n1. Adult out-of-hospital cardiac arrest patients with initial shockable rhythm\n2. Unconsciousness defined as Glasgow Coma Scale \\\u003C 8\n3. Inclusion within 20 minutes from EMS arrival\n\nEXCLUSION CRITERIA:\n\nPatients are not eligible if they meet one or more of the following criteria:\n\n1. Age ≥ 80 years\n2. Obvious non-cardiac causes to cardiac arrest\n3. Obvious already hypothermic\n4. Obvious barrier to placing intra nasal catheters\n5. Have a known Do Not Attempt to Resuscitate (DNAR) order or other limitations in care\n6. Have a known terminal disease\n7. Known or clinically apparent pregnancy","79 Years",{"count":320,"type":20},1022,[23],"The aim of this clinical trial is to study the impact of ultra-early transnasal evaporative cooling after cardiac arrest and subsequent hypothermia at hospital, on survival with complete neurologic recovery, compared to currently recommended normothermia. The study population will consist of patients 18-79 years old, with out-of-hospital cardiac arrest with initial shockable rhythm.\n\nThe main research question it aims to answer is whether there is a difference in survival with complete neurologic recovery at 90 days after cardiac arrest between the group of patients that received ultra-early cooling, compared to the group that was treated with normothermia.\n\nParticipants will be randomized to two groups. One group (the intervention group) will receive ultra-early trans-nasal evaporative cooling initiated by EMS personnel at the scene of the cardiac arrest, and subsequent systemic hypothermia for 24 hours at hospital arrival. The other group (the control group), will receive standard of care (advanced cardiac life support and normal body temperature (normothermia)).",[175,324,27],"Hypothermia",[326,327,328,329,330,331],"Therapeutic hypothermia","transnasal cooling","neurologic outcome","ultrafast hypothermia","prehospital","ECPR","2025-09-19",{"date":334,"type":36},"2025-09-25",{"date":336,"type":36},"2024-03-27",{"date":338,"type":20},"2028-05",{"name":340,"class":113},"Karolinska Institutet",11,{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":114},"100594064","using-heart-electrical-signals-to-study-how-well-treatments-prevent-dangerous-heart-rhythms-in-active-people-100594064","NCT07014579","Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People","Utilizing LifeMap To Investigate Malignant Arrhythmia Therapeutic Efficacy in Athletes","ULTIMATE-A","Inclusion Criteria:\n\n* Age 18 and over.\n* Participates in regular physical activity for at least 3 hours or greater weekly.\n* Having Implantable cardioverter defibrillator insitu (cases).\n* Having a cardiac pacemaker (control).\n* Having no cardiac device (control).\n* Sufficient capacity and agreement to participate orally and signed written consent forms.\n* Understanding of written and spoken English language.\n\nExclusion Criteria:\n\n* Pregnancy, as detected by positive urine pregnancy test result.\n* Inability to comply with study protocols.\n* Any iatrogenic cardiac pathology (stents, CABG etc).\n* Unstable ventricular tachycardia (\\>30 seconds).\n* Any unstable malignant arrhythmia.\n* Fever or presence of a clinically diagnosed febrile illness",{"count":171,"type":20},"The goal of this observational study is to learn if two specific heart electrical signal patterns can help in detecting the risk of dangerous heart rhythms in athletes, and to see if exercise-based tests can be used instead of invasive hospital procedures to record this electrical signals.\n\nThe main questions it aims to answer are:\n\n1. Can special ECG action potential duration markers (R2I2 and PERS) identify athletes who are at higher risk of sudden heart rhythm problems.\n2. Can an exercise test give the same information as a non-invasive electrophysiology study.\n\nResearchers will compare athletes who have an implanted heart device (ICD) with athletes who do not, to see if there are differences in these heart signals.\n\nParticipants will undergo:\n\n1. ECG recordings during rest and exercise.\n2. If they have an ICD or pacemaker, an ECG will be recorded during a non invasive stimulation.\n3. A continuous 24 hour ECG.",[353,293,354,355,27],"Inherited Cardiac Conditions","Ventricular Arrhythmia","Athlete",[357,358,359,360,354,27,361],"ULTIMATE-Athlete","LifeMap","R2I2","PERS","Sudden Cardiac Death","2025-06-09",{"date":364,"type":36},"2025-06-11",{"date":366,"type":20},"2025-06-01",{"date":77,"type":20},{"name":369,"class":113},"University of Leicester",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":21,"phases":380,"briefSummary":381,"conditions":382,"keywords":383,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":114},"100567743","initial-double-sequential-external-defibrillation-in-out-of-hospital-cardiac-arrest-100567743","NCT06672159","Initial Double Sequential External Defibrillation in Out of Hospital Cardiac Arrest","A Randomized Controlled Trial on Early Double External Sequential Defibrillation in Out of Hospital Cardiac Arrest","DUALDEFIB","Inclusion Criteria:\n\n* Patients with out of hospital cardiac arrest presenting with a shockable rhythm\n\nExclusion Criteria:\n\n* Age below 18 years\n* Obvious or suspected pregnancy\n* Incarcerated patients\n* Preexisting do-not-resuscitate order",{"count":379,"type":20},356,[23],"Double Sequential External Defibrillation (DSED) represents an alternative treatment of refractory ventricular fibrillation (rVF) in out-of-hospital cardiac arrest (OHCA). The procedure consists of two defibrillators that administer shocks at the same time.\n\nCurrently, the procedure is not initiated before at least three failed attempts with one defibrillator. This can delay the potential benefits of establishing DSED earlier in the treatment. Studies have shown that early defibrillation is crucial for survival in OHCA patients, and in 2022, a clinical trial showed that survival in patients treated with DSED was higher compared to standard treatment.\n\nThe effect of initiating OHCA treatment is unknown. The DUALDEFIB trial seeks to investigate if treating OHCA patients with DSED as an initial treatment will increase survival and provide improved neurological outcome.",[176,175,27],[384,385],"Double defibrillation","Cardiopulmonary resuscitation","2025-06-04",{"date":388,"type":36},"2025-06-05",{"date":390,"type":36},"2025-04-28",{"date":392,"type":20},"2028-10",{"name":394,"class":113},"St. Olavs Hospital",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":403,"targetDuration":405,"studyType":67,"phases":4,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":421},"100494650","in-hospital-stellate-ganglion-block-for-arrhythmic-storm-100494650","NCT05720936","In-hospital Stellate Ganglion Block for Arrhythmic Storm","A Multicenter Observational Study on In-hospital Stellate Ganglion Block for Arrhythmic Storm","STAR","Inclusion Criteria:\n\n* age ≥ 18 years,\n* presence of arrhythmic storm defined as more than three sustained ventricular arrhythmias in 24 hours refractory to the standard medical treatment.\n\nExclusion Criteria:\n\n* A previous history of cardiac sympathicectomy\n* Having a neck judged unsuitable for the procedure (previous neck surgery, previous burns, presence of large scars, thyroid goiter)\n\nBoth the two approaches present in literature and commonly used for this technique are allowed for the study:\n\n* The \"anatomical\" approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion\n* The \"echo-guided\" approach Regardless to the approach (anatomical or echo-guided) the doctor will be able to choose, according to the clinical characteristics of the patients, whether to perform a single shot injection of anesthetic or a continuous infusion of anesthetic. In the second case a catheter will be left in place and connected to an infusion pump.",{"count":404,"type":20},500,"1 Day","Arrhythmic storm is a real emergency and its treatment could be challenging. Antiarrhythmic drugs are few and often ineffective. Neuromodulation has been grown in evidences but no large multicentric studies are present in literature about safety and effectiveness of Percutaneous Stellate Ganglion Block (PSGB). Patients with an electrical storm refractory to at least one antiarrhythmic drug will receive PSGB and will be enrolled in the present study.\n\nThe number of defibrillations before and after the treatment will be compared, complications will be annotated.",[408,263,27,28],"Arrhythmic Storm",[410,411,412,413,263],"PSGB","L-PSGB","Percutaneous Stellate Ganglion Block","Percutaneous Stellate Ganglion Blockade",{"date":415,"type":36},"2025-06-08",{"date":417,"type":36},"2017-11-07",{"date":40,"type":20},{"name":420,"class":113},"Fondazione IRCCS Policlinico San Matteo di Pavia",38,{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":21,"phases":433,"briefSummary":434,"conditions":435,"keywords":438,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":4},"100577980","the-osiris-ecpr-trial-100577980","NCT06805344","The OSIRIS ECPR Trial","Out-of-hospital Refractory Cardiac Arrest Treated with Extracorporeal Cardiopulmonary Resuscitation","OSIRIS","Inclusion Criteria:\n\n1. Age ≥18 and ≤ 70 years presumed or known\n2. Witnessed OHCA\n3. Bystander CPR provided\n4. Presumed cardiac or unknown cause\n5. An initial documented shockable rhythm of VF (ventricular fibrillation) or pulseless VT (ventricular tachycardia)\n6. Minimum of ≥ 10 min of ACLS without ROSC or at least ≥ 3 defibrillations in ongoing VF\u002Fpulseless VT\n7. Body morphology able to accommodate a mechanical chest compression device\n8. ECPR team and intensive care unit (ICU) capacity in the receiving center available\n9. Estimated transfer time from the scene to the hospital ≤ 30 minutes or to the scene ≤ 30 minutes\n10. Eligible for intensive care without restrictions or limitations\n\nExclusion Criteria:\n\n1. ACLS ≥ 30 minutes before randomization\n2. Known limitations in care or a Do Not Attempt to Resuscitate (DNAR) order\n3. Known severe disease making 90-day survival unlikely\n4. Known bleeding diathesis or acute or recent intracranial bleeding\n5. Known, obvious or suspected pregnancy\n6. Known pre-arrest severe cognitive dysfunction (mRS ≥ 4)\n7. Known hypothermia as a cause of cardiac arrest","70 Years",{"count":432,"type":20},686,[23],"The OSIRIS trial is an investigator-initiated, multicenter, multinational, open-label, randomized controlled trial with a 2:1 concealed allocation of refractory out-of-hospital cardiac arrest (OHCA) patients to the extracorporeal cardiopulmonary resuscitation (ECPR) based approach versus the conventional cardiopulmonary resuscitation (CCPR) approach.",[176,27,175,293,436,437],"Extracorporeal Cardiopulmonary Resuscitation","Extracorporeal Membrane Oxygenation",[439,440,441,296],"cardiac arrest","extracorporeal cardiopulmonary resuscitation","extracorporeal membrane oxygenation","2025-01-30",{"date":444,"type":36},"2025-02-03",{"date":446,"type":20},"2025-02",{"date":448,"type":20},"2030-06",{"name":450,"class":113},"General University Hospital, Prague",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":21,"phases":461,"briefSummary":462,"conditions":463,"keywords":467,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":114},"100406723","a-danish-icd-study-in-patients-with-coronary-artery-disease-resuscitated-from-ventricular-fibrillation-100406723","NCT04576130","A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation","A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation Who Receive Complete Revascularization","DanICD","Inclusion Criteria:\n\n* Patients with CAD and cardiac arrest due to VF\u002FVT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.\n* Age ≥18 years\n* LVEF \\>35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.\n\nExclusion Criteria:\n\n* Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)\n* Previous CABG within the last 3 months before index hospitalization\n* Life expectancy less than 1 year or severe neurologic outcome\n* Unable or unwilling to give informed consent\n* Pregnancy",{"count":460,"type":20},1200,[23],"DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation\u002Fsustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.",[464,465,27,466,175],"Coronary Artery Disease","Acute Myocardial Infarction","Ventricular Tachycardia, Sustained",[468,469,470],"Revascularization","Percutaneous coronary intervention","Implantable cardioverter defibrillator","2025-01-23",{"date":473,"type":36},"2025-01-27",{"date":475,"type":36},"2020-10-12",{"date":477,"type":20},"2032-10",{"name":479,"class":113},"Rigshospitalet, Denmark",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":490,"conditions":491,"keywords":513,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":534},"100541040","contemporary-cardiac-stimulation-in-clinical-practice-left-biventricular-right-and-conduction-system-pacing-100541040","NCT06324682","ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","Evaluation of conTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","TREEBEARD","Inclusion Criteria:\n\n* Indication for cardiac stimulation\n* Having performed the implantation of a device for cardiac stimulation\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Pregnancy status;",{"count":489,"type":20},8400,"The goal of this observational study is to evaluate the clinical characteristics of patients undergoing permanent cardiac pacing and to compare procedural efficacy and safety of different implantation approaches in the clinical practice of the participating centres. The contribution of non-fluoroscopic anatomical and electrophysiological reconstruction systems to device implantation procedures will also be evaluated.\n\nParticipants \\[patients over 18 years old with an indication to receive a definitive pacemaker\u002Fintracardiac defibrillator implant\\] will receive a permanent cardiac pacing implant as requested according to European Society of Cardiology (ESC) guidelines; the investigators will evaluate procedural efficacy and safety of different implantation approaches.",[492,493,494,103,495,28,496,27,26,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512],"Arrhythmias, Cardiac","Atrioventricular Block","Reduced Systolic Function","Bradyarrhythmia","Ventricular Dysfunction","Atrioventricular Nodal Disease","Atrioventricular Conduction Defects","Atrioventricular Block Complete","Atrioventricular Block Incomplete","Atrioventricular Junctional Rhythm","Bundle-Branch Block","Left Bundle-Branch Block","Heart Failure, Systolic","Block;Atrioventricular","Block; Arrhythmic","Block; Mobitz","Block, Heart","Block, Fascicular","Block Branch Bundle Left","Heart Failure，Congestive","Heart Arrhythmia",[514,515,493,495,496,516,517,518,519,520,521,522,523,499,524,26,27,28],"Pace maker (PM)","Implantable cardioverter defibrillator (ICD)","Cardiac Resynchronization therapy","Conduction System Pacing","His Pacing","Left bundle branch area pacing (LBBAP)","CRT","CSP","Primary prevention","Secondary prevention","Heart failure","2024-03-19",{"date":527,"type":36},"2024-03-22",{"date":529,"type":36},"2023-01-01",{"date":531,"type":20},"2034-12-31",{"name":533,"class":113},"University Hospital of Ferrara",31,{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":21,"phases":545,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":114},"100536812","magnetic-resonance-imaging-guided-implantation-of-cardioverter-defibrillators-100536812","NCT06269692","MAgnetic Resonance Imaging-guided implanTation of Cardioverter DEFibrillators","Multicenter randomiSed Trial on MAgnetic Resonance Imaging-guided implanTation of Cardioverter DEFibrillators","SMART-DEF","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Patients with a LVEF≤35% assessed at least after a 40 to 90 days period (depending on the presence of coronary revascularization) following an index myocardial infarction;\n* Left ventricular systolic impairment as defined by LVEF≤35% by any current standard technique (echocardiogram, multiple gated acquisition scan, or MRI) within 2 months;\n* Able and willing to comply with all pre-, post- and follow-up testing, and requirements;\n* Use of maximum tolerated doses of ACE inhibitors (or Angiotensin II Receptor Blockers if intolerant of ACE) and Beta Blockers and MRA as per ESC guidelines;\n* Person affiliated to or beneficiary of a social security plan\n* Person informed about study organization and having signed the informed consent\n\nExclusion Criteria:\n\n* History of cardiac arrest or sustained VT or VF unless within 48 hours of an acute myocardial infarction;\n* Standard contraindications for cardiac LGE-MRI;\n* Hypersensitivity to gadolinium-based contrast agent;\n* Currently implanted permanent pacemaker and\u002For ICD;\n* Patient refusal of ICD\u002FILR implantation;\n* Currently implanted permanent pacemaker and\u002For ICD;\n* Clinical indication for or Cardiac Resynchronization Therapy (CRT);\n* Severe renal insufficiency defined by a glomerular filtration rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73m²;\n* Recent PTCA (within 30 days) or CABG (within 90 days);\n* Baseline NYHA functional class IV;\n* Contraindication for ICD implantation according to current guidelines;\n* Woman of childbearing age without effective contraception;\n* Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the French Public Health Code.",{"count":544,"type":20},1812,[23],"Implantable cardioverter-defibrillators (ICD) are currently recommended for the primary prevention of sudden cardiac death (SCD) in patients with a remote (\\>6 weeks) myocardial infarction (MI) and a low (≤35%) left ventricular ejection fraction (LVEF).\n\nVentricular tachycardia (VT) and\u002For ventricular fibrillation (VF), which are responsible for most SCDs, result from the presence of surviving myocytes embedded within fibrotic MI-scar. The presence of these surviving myocytes, as well as their specific arrhythmic characteristics, is not captured by LVEF. Hence, the use of LVEF as a unique risk-stratifier of SCD results in a low proportion (17 to 31%) of appropriate ICD device therapy at 2 years. Consequently, most patients with a prophylactic ICD do not present VT\u002FVF requiring ICD therapy prior to their first-ICD battery depletion. Thus, many patients are exposed to ICD complications, such as inappropriate shocks, without deriving any health benefit. Therefore, the current implantation strategy of prophylactic ICDs, based on LVEF only, needs to be improved in post-MI patients.",[548,28,27,361],"Myocardial Infarction",[548],"2024-02-19",{"date":552,"type":36},"2024-02-21",{"date":554,"type":20},"2024-04-01",{"date":556,"type":20},"2030-04-01",{"name":558,"class":113},"Central Hospital, Nancy, France",{"id":560,"slug":561,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":566,"targetDuration":568,"studyType":67,"phases":4,"briefSummary":569,"conditions":570,"keywords":574,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":114},"100313420","registry-of-device-implantation-100313420","NCT03360227","Registry of Device Implantation","Registry of Device Implantation in University Hospital Duesseldorf","Inclusion Criteria:\n\n1. pre-operative clinical history taking\n2. pre-operative functional investigations (cardiac echo, electrocardiograms)\n3. pre-operative laboratory data evaluation (kidney function, liver function, biomarkers, thyroid hormone, CBC)\n\nExclusion Criteria:\n\n１. no written informed consent",{"count":567,"type":20},2000,"24 Months","The implantable device therapy for cardiac arrhythmias has been an established therapy, and one of the common standard procedures in cardiac clinical practice.\n\nPacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy have been developed since 1960s, and the technologies in this field are still progressively developing. Not only these \"traditional\" implantable devices, there are multiple new devices for cardiac diseases, such as implantable loop recorder, vagal nerve stimulator and barostimulator.\n\nThe aim of this registry is to demonstrate the efficacy and the safety of standard device implantation procedures and to evaluate\u002F identify specific factors, including clinical characteristics, laboratory data and procedural data, which predict the prognosis\u002Fcomplication of the patients. These identification will result in further improvement of patients' care.",[571,572,573,361,28,27],"Syncope","Bradycardia","Tachycardia",[575,576,577,578,579,580,581,582,583],"syncope","bradycardia","tachycardia","sudden cardiac death","implantable cardioverter-defibrillator","ventricular tachycardia","ventricular fibrillation","biomarker","thyroid hormone","2020-02-06",{"date":586,"type":36},"2020-02-07",{"date":588,"type":36},"2011-01",{"date":590,"type":20},"2030-12",{"name":592,"class":113},"Klinik für Kardiologie, Pneumologie und Angiologie"]